Description: ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Home Page: www.chemocentryx.com
CCXI Technical Analysis
835 Industrial Avenue
San Carlos,
CA
94070
United States
Phone:
650 210 2900
Officers
| Name | Title |
|---|---|
| Dr. Thomas J. Schall Ph.D. | Founder, Pres, CEO & Chairman |
| Ms. Susan M. Kanaya | Exec. VP, Chief Financial & Admin. Officer, Sec. and Director |
| Mr. Tausif Butt | Exec. VP & COO |
| Dr. Rita I. Jain M.D. | Exec. VP, Chief Medical Officer & Exec. Employee Director |
| Dr. Markus J. Cappel Ph.D. | Chief Bus. Officer & Treasurer |
| Ms. Yi Ching Yau | Sr. VP of Fin. & Principal Accounting Officer |
| Mr. William S. Slattery | VP of Investor Relations & Corp. Communications |
| Ms. Kari E. Leetch | Sr. VP of HR |
| Dr. Sangita Ghosh Ph.D. | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.8082 |
| Price-to-Sales TTM: | 100.2979 |
| IPO Date: | 2012-02-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 178 |